Alnylam Just Bet $1.1 Billion on a Tiny Heart Disease Company

That's where Tenaya comes in. Founded in 2016 by scientists from the Gladstone Institutes and UT Southwestern Medical Center, the company was built specifically to decode the genetic roots of heart disease. Their team uses human iPSC-derived cardiomyocytes (essentially heart cells grown from stem cells in a lab) to test which genetic mutations actually drive disease. It's painstaking, specialized work, and very few companies do it at this level.

For Tenaya, the benefits are equally clear. They get capital, credibility, and a partner who can turn validated targets into real drugs. Tenaya already has its own clinical programs: TN-201, a gene therapy for hypertrophic cardiomyopathy (a condition where the heart muscle gets dangerously thick), and TN-401, a gene therapy for arrhythmogenic right ventricular cardiomyopathy (a rare disease where heart muscle is replaced by scar tissue). Both are in early clinical trials. But those programs use AAV gene therapy, a completely different approach from RNAi. This deal lets Tenaya's target-hunting expertise feed into a second, complementary technology.

The Billion-Dollar Asterisk

Let's be honest about that $1.13 billion number. It sounds massive, and it is; if every single one of those 15 targets leads to an approved drug for cardiovascular disease. In reality, drug development is a brutal funnel. Roughly 90% of drugs that enter clinical trials never make it to approval.

So while the theoretical ceiling is sky-high, Tenaya's guaranteed money is much more modest: up to $10 million upfront, plus research costs covered during the two-year validation period. The rest comes in development and commercial milestones that could take a decade or more to materialize.

Still, even a fraction of that total would be transformative for a company of Tenaya's size. If just two or three targets produce approved therapies, we're talking hundreds of millions in milestone payments flowing back to the company.

RNAi's Cardiovascular Moment

This deal doesn't exist in a vacuum. It's part of a broader wave of RNAi investment pouring into cardiovascular medicine.

Alnylam is already partnered with Roche on zilebesiran, an RNAi drug for hypertension that's in Phase 3 trials. It works by silencing angiotensinogen, the most upstream precursor in the blood pressure regulation system. Instead of managing blood pressure downstream (like most current drugs), it goes straight to the source.

Meanwhile, inclisiran became the first approved RNAi therapy for high cholesterol, achieving roughly 50% sustained LDL reduction with infrequent dosing. And a startup called Corsera Health raised $80 million in Series A funding to develop its own RNAi cardiovascular programs.

The thesis is becoming consensus: RNA-based medicines can do for cardiology what they've already started doing for rare diseases. Heart disease is the biggest market in all of medicine, and RNAi companies are circling it like sharks who just smelled blood in the water.

What to Watch

The next two years will be telling. Tenaya needs to validate targets that are genuinely druggable, not just scientifically interesting. Alnylam needs to demonstrate that its RNAi platform can effectively silence genes in heart tissue, not just the liver (where most current RNAi drugs work). The company is developing a new delivery technology called the C16 platform that aims to extend RNAi's reach into the central nervous system, which would be a game-changer if it works.

For Tenaya investors, the near-term impact is the upfront payment and research funding, both of which extend the company's runway while its gene therapy programs (TN-201 and TN-401) continue through clinical trials. CEO Faraz Ali has been vocal about building a multi-modal approach to heart disease, combining gene therapy, small molecules, and now RNAi through this partnership.

For the broader cardiovascular field, this deal is a signal. The biggest RNAi company in the world just decided that heart disease genetics is worth over a billion dollars in potential investment. When Alnylam writes a check that large, people in boardrooms across pharma sit up and pay attention.

The heart has always been one of medicine's toughest organs to treat at the genetic level. This partnership is a bet that the tools have finally caught up to the ambition.

The Neuralink Rival That Just Raised $230M to Fix Blindness

A Neuralink co-founder's new company just raised $230 million to implant rice-grain-sized devices in people's eyes. Science Corporation is now valued at $1.5 billion, and it could launch its vision-restoring retinal implant in Europe within months.